What is ilosone?
Ilosone is the brand name for erythromycin, a macrolide antibiotic that has been a foundation of antimicrobial therapy for over six decades. Erythromycin was first isolated in 1952 from the soil bacterium Saccharopolyspora erythraea, and it represented the first clinically useful member of the macrolide class of antibiotics. The name macrolide derives from the large macrocyclic lactone ring that is the defining structural feature of these compounds. Ilosone exerts its antibacterial activity by binding to the bacterial ribosome and inhibiting protein synthesis, thereby preventing bacterial growth and replication. The drug is active against many gram-positive bacteria, many gram-negative organisms, and certain atypical pathogens including mycoplasmas, chlamydiae, and legionellae.
Erythromycin is available in various salt forms and formulations designed to optimize its pharmacokinetic properties and tolerability. The base form of erythromycin is acid-labile and can be degraded by gastric acid, leading to variable and unpredictable absorption. To address this limitation, Ilosone contains erythromycin estolate, an esterified formulation that is more stable in the presence of gastric acid and that provides more reliable and predictable oral absorption. Erythromycin estolate is a lauryl sulfate salt of the propionyl ester of erythromycin, and it is notable for achieving higher and more sustained serum concentrations than other erythromycin formulations. Ilosone has been used for the treatment of a broad spectrum of infections, including those of the respiratory tract, skin, and soft tissues, and for the management of sexually transmitted infections caused by Chlamydia trachomatis and for the prophylaxis of pertussis and diphtheria.
Despite the development of newer macrolide antibiotics such as clarithromycin and azithromycin, which offer improved pharmacokinetic properties and tolerability, erythromycin continues to have a role in clinical practice. It is used when alternative agents are contraindicated or unavailable, and it is a prokinetic agent for the management of delayed gastric emptying due to its ability to stimulate motilin receptors in the gastrointestinal tract. The long history of clinical experience with erythromycin, combined with its well-characterized safety and efficacy profile, continues to make Ilosone a relevant option in selected clinical situations.
How does ilosone work?
The antibacterial mechanism of erythromycin, the active ingredient in Ilosone, involves inhibition of bacterial protein synthesis through binding to the bacterial ribosome. The bacterial ribosome is a complex macromolecular machine responsible for translating the genetic code contained in messenger RNA into proteins that are essential for bacterial survival. The ribosome consists of two subunits, designated 50S and 30S, based on their sedimentation coefficients. Erythromycin binds specifically and with high affinity to the 50S subunit of the bacterial ribosome, targeting a site within the peptide exit tunnel near the peptidyl transferase center.
The exact binding site of erythromycin on the 50S ribosomal subunit has been elucidated through structural studies, including X-ray crystallography of ribosome-antibiotic complexes. Erythromycin interacts with specific nucleotides in the 23S ribosomal RNA of the 50S subunit, forming hydrogen bonds and hydrophobic interactions that stabilize the drug-ribosome complex. The binding of erythromycin occludes the peptide exit tunnel, physically blocking the passage of the nascent polypeptide chain as it is being synthesized. This steric blockade prevents the elongation of the peptide chain and leads to the premature release of incomplete peptidyl-tRNA molecules from the ribosome.
The result of erythromycin binding to the ribosome is the inhibition of bacterial protein synthesis and, depending on the concentration of the drug and the susceptibility of the organism, either a bacteriostatic or bactericidal effect. At typical therapeutic concentrations, erythromycin is primarily bacteriostatic, meaning that it inhibits bacterial growth and replication without directly killing the bacteria. The host’s immune system is then required to clear the inhibited bacteria from the site of infection. At higher concentrations, erythromycin can exhibit bactericidal activity against particularly susceptible organisms. The bacteriostatic nature of erythromycin has implications for its clinical use, particularly in patients who are immunocompromised and may be less able to eradicate inhibited bacteria through their own immune defenses.
The selectivity of erythromycin for bacterial ribosomes over human ribosomes is based on structural differences between the prokaryotic and eukaryotic protein synthesis machinery. Erythromycin binds much less avidly to human ribosomes, which explains its limited direct toxicity to human cells. However, the mitochondrial ribosomes of human cells bear greater structural similarity to bacterial ribosomes than do cytoplasmic ribosomes, which may account for some of the adverse effects of macrolide antibiotics. The spectrum of activity of erythromycin encompasses many gram-positive bacteria including Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aureus, and Corynebacterium diphtheriae. It is also active against certain gram-negative organisms including Haemophilus influenzae, Neisseria gonorrhoeae, and Bordetella pertussis. Also, erythromycin has activity against atypical pathogens including Mycoplasma pneumoniae, Chlamydia trachomatis, Chlamydophila pneumoniae, Legionella pneumophila, and Ureaplasma urealyticum.
Indications and uses of ilosone
Ilosone is indicated for the treatment of various bacterial infections caused by susceptible organisms. The selection of erythromycin as the appropriate antimicrobial agent for a particular infection should be based on the known or suspected causative pathogen, its expected susceptibility to erythromycin, the site and severity of the infection, patient factors including age, comorbidities, and medication history, and the availability of alternative treatment options.
Respiratory tract infections
Erythromycin is used in the treatment of a range of respiratory tract infections. Community-acquired pneumonia caused by Mycoplasma pneumoniae or Chlamydophila pneumoniae, both of which are susceptible to macrolide antibiotics, is a common indication for erythromycin therapy. The drug provides effective coverage against these atypical respiratory pathogens, which are not susceptible to beta-lactam antibiotics such as penicillins and cephalosporins. Erythromycin may also be used for the treatment of Legionnaires disease, a severe form of pneumonia caused by Legionella pneumophila. Macrolide antibiotics have historically been considered the drugs of choice for this infection, although fluoroquinolones are now often preferred.
Pertussis, commonly known as whooping cough, is another respiratory infection for which erythromycin is used, both for treatment of active infection and for post-exposure prophylaxis in close contacts of infected individuals. The drug shortens the duration of infectivity and can reduce the severity of illness if administered early in the course of the disease. Diphtheria, caused by Corynebacterium diphtheriae, can be treated with erythromycin as an adjunct to diphtheria antitoxin, with the antibiotic serving to eliminate the organism from the respiratory tract and prevent transmission to others. Erythromycin may also be used for the treatment of acute pharyngitis caused by group A Streptococcus in patients who are allergic to penicillin.
Dermatologic infections
Erythromycin is a valuable agent for the treatment of acne vulgaris, a common chronic skin condition involving the pilosebaceous units. The antibacterial activity of erythromycin against Cutibacterium acnes, a bacterium implicated in the pathogenesis of acne, contributes to its therapeutic effect. Both topical and oral formulations of erythromycin have been used for acne management, typically in combination with other acne treatments such as benzoyl peroxide or topical retinoids. The use of oral erythromycin for acne has declined in some regions due to concerns about bacterial resistance and the availability of other effective oral antibiotics with more favorable dosing schedules.
Other skin and soft tissue infections that may be treated with erythromycin include erysipelas, cellulitis, impetigo, and folliculitis when caused by susceptible organisms. However, the increasing prevalence of community-acquired methicillin-resistant Staphylococcus aureus and the variable susceptibility of this organism to erythromycin has limited the reliability of the drug as empiric therapy for skin infections. Culture and susceptibility testing should guide the choice of antibiotic whenever possible.
Sexually transmitted infections
Chlamydia trachomatis infection, the most common bacterial sexually transmitted infection in many parts of the world, can be treated with erythromycin. The drug is effective against the organism and can eradicate genital infection, thereby preventing complications such as pelvic inflammatory disease, ectopic pregnancy, and infertility. However, the gastrointestinal side effects of erythromycin and the need for multiple daily doses over a seven-day course have led to its replacement in this indication by single-dose azithromycin or a seven-day course of doxycycline. Erythromycin remains an alternative for the treatment of chlamydial infections in pregnant women, for whom doxycycline is contraindicated, although azithromycin is often preferred even in this population due to its convenience and tolerability.
Gastrointestinal indications
In addition to its antimicrobial indications, erythromycin is used as a prokinetic agent for the management of gastrointestinal motility disorders. Erythromycin acts as an agonist at motilin receptors in the gastrointestinal tract, stimulating the migrating motor complex and promoting gastric emptying. This prokinetic effect is utilized for diabetic gastroparesis, a condition characterized by delayed gastric emptying in the absence of mechanical obstruction. Low doses of erythromycin administered intravenously or orally before meals can improve gastric emptying and reduce symptoms of nausea, vomiting, bloating, and early satiety in affected patients. The prokinetic effect of erythromycin is also utilized to facilitate the passage of feeding tubes and to clear the stomach of retained contents before emergency procedures.
Dosage and administration
The dosage of Ilosone depends on the type and severity of the infection being treated, the age and weight of the patient, and the specific formulation of erythromycin being used. The medication is administered orally, and the duration of therapy typically ranges from seven to fourteen days for most infections, although longer courses may be prescribed for certain conditions.
Adult dosing
For most infections in adults, the recommended dosage of erythromycin estolate, the formulation contained in Ilosone, is 250 milligrams taken orally every six hours, or 500 milligrams taken orally every twelve hours. The total daily dose typically ranges from one to two grams, depending on the severity of the infection. For more severe infections, the dose may be increased to up to four grams per day in divided doses. The medication should be taken with a full glass of water, and it may be administered with food to reduce gastrointestinal irritation, although high-fat meals may delay absorption.
Pediatric dosing
In pediatric patients, the dosage of erythromycin is based on body weight. The standard pediatric dosage for most infections is 30 to 50 milligrams per kilogram per day, divided into four doses administered every six hours. For more severe infections, the dose may be doubled, up to a maximum of four grams per day. The erythromycin estolate formulation offers the advantage of less frequent dosing in some situations, with 30 to 50 milligrams per kilogram per day administered in two to three divided doses. When prescribing erythromycin for infants, particular attention should be given to the dose and formulation used, as specific pediatric formulations are available that are distinct from those intended for adults.
Dosing in specific infections
For the treatment of pertussis, erythromycin is typically administered at a dose of 40 to 50 milligrams per kilogram per day, divided into four doses, for a duration of fourteen days. For the treatment of chlamydial urogenital infections, erythromycin is typically administered at a dose of 500 milligrams four times daily for seven days. For the treatment of acne vulgaris, lower doses are often used, typically in the range of 250 to 500 milligrams twice daily. For the prokinetic indication, very low doses of erythromycin are used, typically 50 to 250 milligrams three to four times daily before meals, which is far below the doses required for antibacterial activity.
Side effects of ilosone
The adverse effect profile of Ilosone is dominated by gastrointestinal effects, which can be a significant cause of patient intolerance and the need for discontinuation of therapy. Other adverse effects involve the hepatic, cardiovascular, and nervous systems.
Gastrointestinal effects
Gastrointestinal side effects are the most common adverse effects of erythromycin and the primary reason that patients often have difficulty tolerating the medication. These effects include nausea, vomiting, abdominal pain, cramping, and diarrhea. The gastrointestinal effects are related to the motilin agonist activity of erythromycin, which stimulates contractions of the gastrointestinal smooth muscle and can produce symptoms that mimic those of the motor disorders for which the drug is used as a therapeutic prokinetic agent at lower doses.
The incidence and severity of gastrointestinal side effects are dose-related, with higher doses and the administration of the drug on an empty stomach being associated with a greater likelihood of symptoms. Taking erythromycin with food may reduce upper gastrointestinal symptoms but may also delay drug absorption. The selection of the estolate formulation contained in Ilosone may offer some advantages in terms of gastrointestinal tolerability compared to other erythromycin formulations, as the estolate ester is less irritating to the gastric mucosa than the base form of the drug. Nevertheless, gastrointestinal complaints remain common with all erythromycin formulations, and patients should be counseled about what to expect and how to manage these symptoms.
Hepatotoxicity
Erythromycin estolate has been associated with a characteristic form of hepatotoxicity that manifests as cholestatic hepatitis. This adverse effect typically presents with the acute onset of abdominal pain, nausea, vomiting, and jaundice after one to two weeks of therapy. Laboratory abnormalities include elevated serum transaminases, alkaline phosphatase, and bilirubin levels, with a predominantly cholestatic pattern. The hepatitis associated with erythromycin estolate is thought to represent a hypersensitivity reaction rather than a direct toxic effect, and it generally resolves upon discontinuation of the drug. However, rare cases of severe hepatic injury have been reported.
The risk of hepatotoxicity with erythromycin appears to be higher with the estolate salt formulation than with other erythromycin formulations, which is a consideration in the selection of the appropriate erythromycin product for a given patient. Patients with pre-existing liver disease may be at increased risk for hepatotoxicity, and erythromycin estolate should be used with caution in this population, with consideration of alternative antibiotic options. Liver function should be monitored in patients who develop symptoms suggestive of hepatitis during therapy.
Cardiovascular effects
Erythromycin, like other macrolide antibiotics, can prolong the QT interval on the electrocardiogram by blocking cardiac potassium channels, specifically the rapidly activating delayed rectifier potassium current. This effect can predispose to the development of a potentially life-threatening ventricular arrhythmia known as torsades de pointes. The risk of QT prolongation and torsades de pointes is increased when erythromycin is used in combination with other QT-prolonging medications, in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia, in patients with pre-existing cardiac disease or congenital long QT syndrome, and when the drug is administered intravenously at high doses.
Healthcare providers should obtain a thorough history of cardiac disease and review all concomitant medications before prescribing erythromycin. An electrocardiogram may be considered before initiating erythromycin therapy in patients with risk factors for QT prolongation. The concurrent use of erythromycin with other drugs that prolong the QT interval, including certain antiarrhythmics, antipsychotics, and other macrolide or fluoroquinolone antibiotics, should generally be avoided. Patients should be counseled to report any symptoms suggestive of cardiac arrhythmia, such as palpitations, syncope, or near-syncope, during erythromycin therapy.
Other adverse effects
Hypersensitivity reactions to erythromycin, including skin rash, urticaria, and, rarely, anaphylaxis, can occur. Patients with a known allergy to erythromycin or any other macrolide antibiotic should not receive the drug. The potential for cross-allergenicity between different macrolide antibiotics is not fully characterized, and caution is warranted when prescribing a macrolide to a patient with a history of an allergic reaction to another member of the class.
Visit Happy Family Pharmacy for more information on Ilosone
Ototoxicity, particularly hearing loss and tinnitus, has been reported with erythromycin, typically in association with high doses or prolonged therapy. Sensorineural hearing loss has been described, predominantly in elderly patients and those with renal impairment. The hearing loss is generally reversible upon dose reduction or discontinuation of the drug. Neurologic effects, including headache, dizziness, and confusional states, have been reported with erythromycin. In infants, erythromycin has been associated with an increased risk of infantile hypertrophic pyloric stenosis when administered in the first few weeks of life, and the use of the drug in this age group should be approached with caution.
Precautions and warnings
Cardiac precautions
The risk of QT interval prolongation and torsades de pointes is the most serious safety concern with erythromycin and other macrolide antibiotics. Before prescribing erythromycin, healthcare providers should review the patient’s medical history for conditions that increase the risk of arrhythmias and should carefully screen the patient’s medication list for other drugs that prolong the QT interval. Electrolyte levels, particularly potassium and magnesium, should be checked and corrected if necessary before initiating therapy. Patients should be counseled to report any new onset of palpitations, dizziness, or fainting while taking erythromycin.
Hepatic precautions
Given the potential for hepatotoxicity, particularly with the estolate formulation, erythromycin should be used with caution in patients with pre-existing liver disease. Baseline liver function tests should be considered, and patients should be monitored for the development of signs or symptoms of hepatic injury during therapy. The drug should be discontinued if jaundice, significant elevations in hepatic transaminases, or other evidence of significant hepatic dysfunction develops. The estolate formulation should be avoided in patients with known or suspected hepatic impairment when possible.
Pregnancy and lactation
Erythromycin is classified as Pregnancy Category B, and it is one of the antibiotics commonly used during pregnancy when treatment for bacterial infections is required. The drug crosses the placenta, but fetal concentrations are generally low. Erythromycin estolate has been associated with an increased risk of hepatotoxicity in pregnant women, and some authorities recommend against the use of the estolate formulation during pregnancy in favor of other erythromycin formulations or alternative antibiotics. Erythromycin is excreted in breast milk and should be used with caution in nursing mothers. Infants exposed to erythromycin through breast milk should be observed for changes in bowel habits and for signs of infantile hypertrophic pyloric stenosis.
Drug interactions
Erythromycin is an inhibitor of the cytochrome P450 enzyme system, particularly the CYP3A4 isoenzyme. This property gives rise to numerous clinically significant drug interactions when erythromycin is co-administered with medications that are metabolized by this pathway. The inhibition of CYP3A4 by erythromycin can lead to elevated plasma concentrations of the co-administered drug, increasing the risk of adverse effects and toxicity. This drug interaction liability is one of the most important factors limiting the utility of erythromycin in patients who are taking multiple medications.
Medications that can have their metabolism inhibited by erythromycin include certain benzodiazepines such as midazolam and triazolam, leading to excessive sedation; warfarin, leading to increased anticoagulant effect and risk of bleeding; theophylline, leading to nausea, vomiting, and cardiac arrhythmias; carbamazepine, leading to neurotoxicity; cyclosporine, leading to nephrotoxicity; and ergot alkaloids, leading to ergotism characterized by severe peripheral vasospasm. The concurrent use of erythromycin with certain statins, particularly lovastatin, simvastatin, and atorvastatin, can increase the risk of myopathy and rhabdomyolysis.
Erythromycin can also interact with other medications through mechanisms beyond CYP3A4 inhibition. Concurrent use with other QT-prolonging drugs increases the risk of cardiac arrhythmias. The use of erythromycin with digoxin can increase digoxin levels in some patients due to the antibiotic’s effect on the gastrointestinal flora that metabolize digoxin. Healthcare providers should conduct a thorough review of all medications a patient is taking before prescribing erythromycin and should avoid the use of erythromycin when safer alternatives are available for patients who are receiving medications with a known potential for interaction.
Storage and handling
Ilosone capsules and tablets should be stored at controlled room temperature, typically between twenty and twenty-five degrees Celsius, in a dry place protected from light. The medication should be kept in its original container, tightly closed, to protect it from moisture. Erythromycin oral suspension should be prepared at the time of dispensing by adding the specified amount of water to the dry powder and shaking well. After reconstitution, the suspension should be stored in the refrigerator, and the bottle should be shaken well before each use. The reconstituted suspension expires after a specified period, typically ten to fourteen days, and any unused portion should be discarded thereafter. As with all antibiotics, patients should be advised to complete the full prescribed course of therapy and not to save leftover medication for future use.
Frequently asked questions about ilosone
Why does ilosone cause stomach upset?
The gastrointestinal side effects of erythromycin, including nausea, stomach pain, and diarrhea, are primarily related to the drug’s activity as a motilin receptor agonist. Motilin is a hormone that stimulates contractions of the smooth muscle in the stomach and intestines, and erythromycin mimics the action of this hormone. This effect is responsible for the therapeutic use of low-dose erythromycin as a prokinetic agent to improve gastric emptying, but at the higher doses used for antibiotic therapy, it can produce unpleasant gastrointestinal symptoms. Taking erythromycin with food may help reduce some of the upper gastrointestinal symptoms, although it can also delay absorption of the drug. If gastrointestinal side effects are severe, patients should consult their healthcare provider, who may recommend strategies to manage the symptoms or consider switching to an alternative antibiotic that is better tolerated.
Can ilosone be used to treat viral infections such as the common cold or the flu?
No, Ilosone is an antibiotic that is effective only against bacterial infections. It has no activity against viruses and will not be effective for the treatment of viral infections such as the common cold, influenza, or viral pharyngitis. The inappropriate use of antibiotics for viral infections contributes to the development of antibiotic resistance, a serious public health problem, and exposes patients to the risk of adverse effects without providing any therapeutic benefit. Healthcare providers should prescribe antibiotics only when there is reasonable evidence of a bacterial infection, and patients should not expect to receive an antibiotic prescription for every illness.
What is the difference between ilosone and other macrolide antibiotics?
Ilosone contains erythromycin estolate, a specific formulation of erythromycin. Other macrolide antibiotics include clarithromycin and azithromycin, which are semisynthetic derivatives with modified chemical structures. Compared to erythromycin, the newer macrolides generally offer improved pharmacokinetic profiles, including better oral absorption, longer half-lives that allow for less frequent dosing, and higher tissue concentrations. They also tend to be better tolerated, with a lower incidence of gastrointestinal side effects. Also, clarithromycin and azithromycin have broader antimicrobial spectra than erythromycin against some important respiratory pathogens. However, erythromycin remains less expensive than the newer agents and continues to be used in settings where cost is a significant consideration or where the specific clinical indication has been well established with erythromycin.
Summary
Ilosone, containing erythromycin estolate, is a macrolide antibiotic that exerts its antibacterial activity through binding to the 50S subunit of the bacterial ribosome and inhibiting protein synthesis. The drug is active against many gram-positive and gram-negative bacteria, and atypical pathogens including mycoplasmas, chlamydiae, and legionellae. Ilosone is indicated for the treatment of respiratory tract infections, dermatologic infections, sexually transmitted infections, and as a prokinetic agent for gastrointestinal motility disorders. The estolate formulation provides improved oral absorption and more predictable pharmacokinetics compared to the base form of erythromycin.
The adverse effect profile of Ilosone is dominated by dose-related gastrointestinal symptoms, which are a common cause of patient intolerance. Cholestatic hepatitis, associated particularly with the estolate formulation, is a recognized adverse effect that requires monitoring. Cardiovascular effects, particularly QT interval prolongation and the risk of torsades de pointes, represent the most important safety concern with erythromycin and necessitate careful screening for risk factors and avoidance of concurrent use with other QT-prolonging medications. Erythromycin is a significant inhibitor of the CYP3A4 enzyme and can produce clinically important drug interactions with many co-administered medications metabolized by this pathway.
Despite the limitations imposed by gastrointestinal intolerance, drug interactions, and the availability of newer macrolide agents with more favorable profiles, Ilosone continues to occupy a place in the antimicrobial options. Its role includes the treatment of infections for which it has established efficacy, the management of specific conditions such as pertussis and diphtheria, and the utilization of its prokinetic effects for gastrointestinal motility disorders. Appropriate patient selection, careful attention to drug interactions and contraindications, and monitoring for adverse effects are essential for the safe and effective use of Ilosone.
Patients should always consult with a qualified healthcare professional before initiating any new medication or making changes to their existing treatment regimen. Individual response to therapy can vary based on factors including age, overall health status, concurrent medical conditions, and concomitant medications. Regular monitoring and follow-up appointments are essential components of safe and effective pharmacotherapy. Healthcare providers should individualize treatment plans based on comprehensive assessment of each patient unique needs and circumstances. Long-term adherence to prescribed therapy is critical for achieving optimal outcomes in chronic disease management and for preventing complications associated with untreated or undertreated conditions. Patients should report any concerning symptoms or side effects to their healthcare provider promptly.